Tagged with CRO,

Global Carlo Toniatti, chief scientific officer of IRBM, gives his insights into how the increased participation of early-stage ventures in the drug R&D process and the plethora of new research approaches that are recalibrating the role of CROs such as IRBM. An experienced oncologist, Toniatti also weighs in on the key…

Singapore IQVIA Biotech JAPAC’s Dr Senthil Sockalingam outlines the evolving needs of the flood of early-stage drug discovery ventures in Asia, how biotechs in the region differ from their counterparts in the US and Europe, and the most important digitalisation trends to emerge from the COVID-19 pandemic.   Almost 50 percent…

China Dr Haijun Dong, recently appointed CEO of BioDuro-Sundia, shares his priorities for the newly merged entity, one of the largest Contract Research, Development and Manufacturing organizations (CRDMOs) in the world, his talent strategy, and the use of AI within the sector.   BioDuro has very strong capabilities on the discovery…

Czech Republic Pavla Nevolová, country head of EastHORN in the Czech Republic, shares the historical roots of the now multinational Czech CRO. Nevolová also shares her insights into the recent evolution of the Czech clinical research landscape and its challenges and opportunities.   Without any doubt, my biggest achievement at EastHORN is…

Czech Republic The Czech Republic boasts a solid clinical research infrastructure and a supportive regulatory environment, meaning that it stands out as one of Central and Eastern Europe’s top destinations for clinical trials. However, a decline in the number of clinical trials in recent years means that Czech stakeholders are looking to…

Czech Republic Petr Vaculík, country manager of PSI CRO, a privately owned Swiss clinical research organization (CRO), describes how the number of clinical trials is decreasing in the Czech Republic, although many continue to capitalize on the country’s universal healthcare system. Vaculík also shares his views on how to retain a strong…

Global In an exclusive and wide-ranging interview, Tom O’Leary, chief information officer (CIO) of leading contract research organisation (CRO), ICON, highlights how data is already revolutionising the CRO industry and the steps that still need to be taken to better match patients with targeted therapies and improve health outcomes. O’Leary also…

Czech Republic Pavla Rozmarová, clinical research associate manager & regional OD for the Czech affiliate of German CRO Scope International, describes how the Czech clinical research landscape has evolved in the past few years and how Scope has moved to employ a younger generation to capitalize on the industry’s technological shift. Moreover,…

Czech Republic Ladislav Drož, CEO of APIGENEX, reveals the company’s strategy to survive after a leadership change and a reshuffling of the small-molecule science operations at their main client, Novo Nordisk. Drož also discusses APIGENEX’s future goals of investing in robotics and automation. APIGENEX’s services include chemistry, experimental pharmacology, clinical pharmacology, registration…

Czech Republic Darina Hrdličková, chairwoman of the Association of Contract Research Organizations in the Czech Republic (ACRO-CZ), gives an overview of her new priorities and mission since taking over the position in 2018, and how dedicated she is to showcase the strengths of the Czech healthcare system and the advantages of the…

Sweden As a worldwide research powerhouse, Sweden is benefiting from the presence of multinational clinical research organizations like PPD. Martina Stenerdal, general manager for PPD in Scandinavia, discusses the company’s 25-year presence in the Nordic region and the unparalleled advantages of conducting clinical studies in Sweden.   Sweden has many startups…

Sweden In a fast-changing Nordic CRO industry, CTC Clinical Trial Consultants has opted to differentiate with a unique one-stop-shop approach. CEO Anders Millerhovf reveals how the relatively young company has managed to take over the Swedish scene. Moreover, he outlines the challenges faced by early clinical development and discusses the strategies…